CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies
Go back to CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies| (NASDAQ: CRSP) | Delayed: 59.13 +0.10 (0.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $59.03 | 52 Week High | $18.88 | |||
| Open | $59.11 | 52 Week Low | $13.75 | |||
| Day High | $59.52 | P/E | N/A | |||
| Day Low | $58.02 | EPS | $0.00 | |||
| Volume | 132,809 | |||||
| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 518.28 +3.29 (0.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $514.99 | 52 Week High | $134.71 | |||
| Open | $515.60 | 52 Week Low | $73.31 | |||
| Day High | $520.42 | P/E | N/A | |||
| Day Low | $514.18 | EPS | $-1.98 | |||
| Volume | 51,562 | |||||
